{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T15:34:08Z","timestamp":1767108848024,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T00:00:00Z","timestamp":1554681600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00415-019-09315-y","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T07:02:56Z","timestamp":1554706976000},"page":"1685-1692","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Amyloid PETs are commonly negative in suspected Alzheimer\u2019s disease with an increase in CSF phosphorylated-tau protein concentration but an A\u03b242 concentration in the very high range: a prospective study"],"prefix":"10.1007","volume":"266","author":[{"given":"Chlo\u00e9","family":"Manca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Th\u00e9r\u00e8se","family":"Rivasseau Jonveaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Roch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Yves","family":"Marie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Karcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zohra","family":"Lamiral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Malaplate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2194-0328","authenticated-orcid":false,"given":"Antoine","family":"Verger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,8]]},"reference":[{"key":"9315_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement J Alzheimers Assoc 14:535\u2013562. \n                    https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"9315_CR2","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.neuint.2009.02.017","volume":"55","author":"K Koopman","year":"2009","unstructured":"Koopman K, Le Bastard N, Martin J-J et al (2009) Improved discrimination of autopsy-confirmed Alzheimer\u2019s disease (AD) from non-AD dementias using CSF P-tau (181P). Neurochem Int 55:214\u2013218. \n                    https:\/\/doi.org\/10.1016\/j.neuint.2009.02.017","journal-title":"Neurochem Int"},{"key":"9315_CR3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3233\/JAD-131838","volume":"41","author":"M Sauv\u00e9e","year":"2014","unstructured":"Sauv\u00e9e M, DidierLaurent G, Latarche C et al (2014) Additional use of A\u03b242\/A\u03b240 ratio with cerebrospinal fluid biomarkers P-tau and A\u03b242 increases the level of evidence of Alzheimer\u2019s disease pathophysiological process in routine practice. J Alzheimers Dis JAD 41:377\u2013386. \n                    https:\/\/doi.org\/10.3233\/JAD-131838","journal-title":"J Alzheimers Dis JAD"},{"key":"9315_CR4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3233\/JAD-121549","volume":"34","author":"A Gabelle","year":"2013","unstructured":"Gabelle A, Dumurgier J, Vercruysse O et al (2013) Impact of the 2008\u20132012 French Alzheimer plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study. J Alzheimers Dis JAD 34:297\u2013305. \n                    https:\/\/doi.org\/10.3233\/JAD-121549","journal-title":"J Alzheimers Dis JAD"},{"key":"9315_CR5","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","volume":"11","author":"O Sabri","year":"2015","unstructured":"Sabri O, Sabbagh MN, Seibyl J et al (2015) Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: phase 3 study. Alzheimers Dement J Alzheimers Assoc 11:964\u2013974. \n                    https:\/\/doi.org\/10.1016\/j.jalz.2015.02.004","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"9315_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40336-015-0102-6","volume":"3","author":"O Sabri","year":"2015","unstructured":"Sabri O, Seibyl J, Rowe C, Barthel H (2015) Beta-amyloid imaging with florbetaben. Clin Transl Imaging 3:13\u201326. \n                    https:\/\/doi.org\/10.1007\/s40336-015-0102-6","journal-title":"Clin Transl Imaging"},{"key":"9315_CR7","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00259-016-3601-4","volume":"44","author":"MJ Pontecorvo","year":"2017","unstructured":"Pontecorvo MJ, Arora AK, Devine M et al (2017) Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging. Eur J Nucl Med Mol Imaging 44:825\u2013837. \n                    https:\/\/doi.org\/10.1007\/s00259-016-3601-4","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"9315_CR8","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1097\/RLU.0000000000001693","volume":"42","author":"NR Harn","year":"2017","unstructured":"Harn NR, Hunt SL, Hill J et al (2017) Augmenting amyloid PET interpretations with quantitative information improves consistency of early amyloid detection. Clin Nucl Med 42:577\u2013581. \n                    https:\/\/doi.org\/10.1097\/RLU.0000000000001693","journal-title":"Clin Nucl Med"},{"key":"9315_CR9","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.2967\/jnumed.114.142109","volume":"55","author":"L Thurfjell","year":"2014","unstructured":"Thurfjell L, Lilja J, Lundqvist R et al (2014) Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads. J Nucl Med 55:1623\u20131628. \n                    https:\/\/doi.org\/10.2967\/jnumed.114.142109","journal-title":"J Nucl Med"},{"key":"9315_CR10","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.3174\/ajnr.A4281","volume":"36","author":"AP Nayate","year":"2015","unstructured":"Nayate AP, Dubroff JG, Schmitt JE et al (2015) Use of standardized uptake value ratios decreases interreader variability of [18F] florbetapir PET brain scan interpretation. AJNR Am J Neuroradiol 36:1237\u20131244. \n                    https:\/\/doi.org\/10.3174\/ajnr.A4281","journal-title":"AJNR Am J Neuroradiol"},{"key":"9315_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.nicl.2017.04.025","volume":"15","author":"S Bullich","year":"2017","unstructured":"Bullich S, Seibyl J, Catafau AM et al (2017) Optimized classification of18F-Florbetaben PET scans as positive and negative using an SUVR quantitative approach and comparison to visual assessment. NeuroImage Clin 15:325\u2013332. \n                    https:\/\/doi.org\/10.1016\/j.nicl.2017.04.025","journal-title":"NeuroImage Clin"},{"key":"9315_CR12","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders (DSM-5\u00ae)","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (DSM-5\u00ae). American Psychiatric Pub, Washington DC"},{"key":"9315_CR13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement J Alzheimers Assoc 7:263\u2013269. \n                    https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"9315_CR14","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M et al (1984) Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s disease. Neurology 34:939\u2013944","journal-title":"Neurology"},{"key":"9315_CR15","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3233\/JAD-160865","volume":"57","author":"C Gervaise-Henry","year":"2017","unstructured":"Gervaise-Henry C, Watfa G, Albuisson E et al (2017) Cerebrospinal fluid A\u03b242\/A\u03b240 as a means to limiting tube- and storage-dependent pre-analytical variability in clinical setting. J Alzheimers Dis JAD 57:437\u2013445. \n                    https:\/\/doi.org\/10.3233\/JAD-160865","journal-title":"J Alzheimers Dis JAD"},{"key":"9315_CR16","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-181146","author":"C Manca","year":"2019","unstructured":"Manca C, Hopes L, Kearney-Schwartz A et al (2019) Assessment of 18F-florbetaben amyloid PET imaging in patients with suspected Alzheimer\u2019s disease and isolated increase in cerebrospinal fluid tau proteins. J Alzheimers Dis. \n                    https:\/\/doi.org\/10.3233\/JAD-181146","journal-title":"J Alzheimers Dis"},{"key":"9315_CR17","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jalz.2012.06.006","volume":"9","author":"J Dumurgier","year":"2013","unstructured":"Dumurgier J, Vercruysse O, Paquet C et al (2013) Intersite variability of CSF Alzheimer\u2019s disease biomarkers in clinical setting. Alzheimers Dement 9:406\u2013413. \n                    https:\/\/doi.org\/10.1016\/j.jalz.2012.06.006","journal-title":"Alzheimers Dement"},{"key":"9315_CR18","doi-asserted-by":"publisher","first-page":"S390","DOI":"10.1016\/j.jalz.2013.06.008","volume":"10","author":"S Lehmann","year":"2014","unstructured":"Lehmann S, Schraen S, Quadrio I et al (2014) Impact of harmonization of collection tubes on Alzheimer\u2019s disease diagnosis. Alzheimers Dement J Alzheimers Assoc 10:S390\u2013S394. \n                    https:\/\/doi.org\/10.1016\/j.jalz.2013.06.008","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"9315_CR19","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.nicl.2017.12.024","volume":"17","author":"A Chetouani","year":"2018","unstructured":"Chetouani A, Chawki MB, Hossu G et al (2018) Cross-sectional variations of white and grey matter in older hypertensive patients with subjective memory complaints. NeuroImage Clin 17:804\u2013810. \n                    https:\/\/doi.org\/10.1016\/j.nicl.2017.12.024","journal-title":"NeuroImage Clin"},{"key":"9315_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.nicl.2018.07.013","volume":"20","author":"L Presotto","year":"2018","unstructured":"Presotto L, Iaccarino L, Sala A et al (2018) Low-dose CT for the spatial normalization of PET images: a validation procedure for amyloid-PET semi-quantification. NeuroImage Clin 20:153\u2013160. \n                    https:\/\/doi.org\/10.1016\/j.nicl.2018.07.013","journal-title":"NeuroImage Clin"},{"key":"9315_CR21","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.2967\/jnumed.115.171652","volume":"57","author":"AM Catafau","year":"2016","unstructured":"Catafau AM, Bullich S, Seibyl JP et al (2016) Cerebellar amyloid-\u03b2 plaques: how frequent are they, and do they influence 18F-florbetaben SUV ratios? J Nucl Med 57:1740\u20131745. \n                    https:\/\/doi.org\/10.2967\/jnumed.115.171652","journal-title":"J Nucl Med"},{"key":"9315_CR22","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1474-4422(11)70077-1","volume":"10","author":"H Barthel","year":"2011","unstructured":"Barthel H, Gertz H-J, Dresel S et al (2011) Cerebral amyloid-\u03b2 PET with florbetaben (18F) in patients with Alzheimer\u2019s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 10:424\u2013435. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(11)70077-1","journal-title":"Lancet Neurol"},{"key":"9315_CR23","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC (1993) The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43:2412\u20132414","journal-title":"Neurology"},{"key":"9315_CR24","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ana.20730","volume":"59","author":"AM Fagan","year":"2006","unstructured":"Fagan AM, Mintun MA, Mach RH et al (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A\u03b242 in humans. Ann Neurol 59:512\u2013519. \n                    https:\/\/doi.org\/10.1002\/ana.20730","journal-title":"Ann Neurol"},{"key":"9315_CR25","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/j.neurobiolaging.2007.03.029","volume":"29","author":"A Forsberg","year":"2008","unstructured":"Forsberg A, Engler H, Almkvist O et al (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29:1456\u20131465. \n                    https:\/\/doi.org\/10.1016\/j.neurobiolaging.2007.03.029","journal-title":"Neurobiol Aging"},{"key":"9315_CR26","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.biopsych.2009.01.027","volume":"65","author":"T Grimmer","year":"2009","unstructured":"Grimmer T, Riemenschneider M, F\u00f6rstl H et al (2009) Beta amyloid in Alzheimer\u2019s disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 65:927\u2013934. \n                    https:\/\/doi.org\/10.1016\/j.biopsych.2009.01.027","journal-title":"Biol Psychiatry"},{"key":"9315_CR27","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.2967\/jnumed.109.064360","volume":"50","author":"N Tolboom","year":"2009","unstructured":"Tolboom N, van der Flier WM, Yaqub M et al (2009) Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med 50:1464\u20131470. \n                    https:\/\/doi.org\/10.2967\/jnumed.109.064360","journal-title":"J Nucl Med"},{"key":"9315_CR28","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1212\/WNL.0b013e3181bc010c","volume":"73","author":"WJ Jagust","year":"2009","unstructured":"Jagust WJ, Landau SM, Shaw LM et al (2009) Relationships between biomarkers in aging and dementia. Neurology 73:1193\u20131199. \n                    https:\/\/doi.org\/10.1212\/WNL.0b013e3181bc010c","journal-title":"Neurology"},{"key":"9315_CR29","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/ana.23908","volume":"74","author":"SM Landau","year":"2013","unstructured":"Landau SM, Lu M, Joshi AD et al (2013) Comparing positron emission tomography imaging and cerebrospinal fluid measurements of \u03b2-amyloid. Ann Neurol 74:826\u2013836. \n                    https:\/\/doi.org\/10.1002\/ana.23908","journal-title":"Ann Neurol"},{"key":"9315_CR30","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/archneurol.2008.596","volume":"66","author":"T Tapiola","year":"2009","unstructured":"Tapiola T, Alafuzoff I, Herukka S-K et al (2009) Cerebrospinal fluid \u03b2-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66:382\u2013389. \n                    https:\/\/doi.org\/10.1001\/archneurol.2008.596","journal-title":"Arch Neurol"},{"key":"9315_CR31","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/WCO.0000000000000502","volume":"30","author":"T Lebouvier","year":"2017","unstructured":"Lebouvier T, Pasquier F, Bu\u00e9e L (2017) Update on tauopathies. Curr Opin Neurol 30:589\u2013598. \n                    https:\/\/doi.org\/10.1097\/WCO.0000000000000502","journal-title":"Curr Opin Neurol"},{"key":"9315_CR32","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/ana.24719","volume":"80","author":"AG Vlassenko","year":"2016","unstructured":"Vlassenko AG, McCue L, Jasielec MS et al (2016) Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease. Ann Neurol 80:379\u2013387. \n                    https:\/\/doi.org\/10.1002\/ana.24719","journal-title":"Ann Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09315-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-019-09315-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09315-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T23:26:26Z","timestamp":1586215586000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-019-09315-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,8]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["9315"],"URL":"https:\/\/doi.org\/10.1007\/s00415-019-09315-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"type":"print","value":"0340-5354"},{"type":"electronic","value":"1432-1459"}],"subject":[],"published":{"date-parts":[[2019,4,8]]},"assertion":[{"value":"18 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was approved by the French ethics committee CPP Est III on September 15th, 2015, as well as received the authorization from the national competent authority (ANSM) on September 18th 2015, and adhered to the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"All patients provided written informed consent for participation in the study. All patients provided written informed consent for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All data generated or analyzed during this study are included in this published article and its supplementary information files.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}}]}}